Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
Jankovic
J
J
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA. josephj@bcm.tmc.edu
Hunter
C
C
Dolimbek
B Z
BZ
Dolimbek
G S
GS
Adler
C H
CH
Brashear
A
A
Comella
C L
CL
Gordon
M
M
Riley
D E
DE
Sethi
K
K
Singer
C
C
Stacy
M
M
Tarsy
D
D
Atassi
M Z
MZ
D001905:Botulinum Toxins / Q000276:immunology* / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D004351:Drug Resistance / Q000187:drug effects / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000276:immunology / Q000627:therapeutic use; D014103:Torticollis / Q000188:drug therapy* / Q000276:immunology*; D014481:United States
D009465:Neuromuscular Agents; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A